Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

(2016) Carlos Taxonera et al.   DIGESTIVE DISEASES AND SCIENCES

Mo1794 Delayed Response to Golimumab Therapy: UC Patient Characteristics and Long-term Clinical Outcome: Post-Hoc Analyses from the PURSUIT Program

(2016) Jean-Frederic Colombel et al.   GASTROENTEROLOGY

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

(2016) Parambir S. Dulai et al.   INFLAMMATORY BOWEL DISEASES

Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies

(2016) Casper Steenholdt et al.   INFLAMMATORY BOWEL DISEASES

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies

(2016) Omoniyi J. Adedokun et al.   Journal of Crohns & Colitis

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

(2016) Marta Maia Bosca-Watts et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis

(2016) Antonio Tursi et al.   Clinics and Research in Hepatology and Gastroenterology

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study

(2016) Christopher Ma et al.   Canadian Journal of Gastroenterology and Hepatology

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases

(2015) Andres J. Yarur et al.   INFLAMMATORY BOWEL DISEASES

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice

(2015) Anita Bálint et al.   Journal of Crohns & Colitis

Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?

(2015) Javier P. Gisbert et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Adalimumab in active ulcerative colitis: A “real-life” observational study

(2013) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease

(2012) P. S. A. Silva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

(2010) C. Taxonera et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS